Diabetes is a progressive chronic disease and is considered as an important health problem, which has increased in recent years. The prevalence of diabetes in the Middle East in 2015 was 35.4 million, which more than 4.6 million people were in Iran. In this review, we specifically tried to summarize the results of clinical trials on the effects of selenium supplementation on glycemic control and lipid profile and inflammatory factors in type 2 diabetic patients. In this review, three interventional studies were included to evaluate the effect of Selenium supplementation on metabolic parameters. Serum insulin concentration and insulin resistance index were significantly reduced in two of the studies. Fasting plasma glucose and HDL cholesterol concentrations significantly increased in one study while in other studies no significant changes were observed. One of the studies showed a significant reduction in inflammatory Indicators and antioxidant capacity, one study also showed a significant decrease in lipid profiles. Selenium supplementation in patients with type 2 diabetes may have adverse effects on blood glucose homeostasis. However, it may improve lipid profile and antioxidant capacity and reduces inflammatory mediators in these patients. Therefore, in spite of the negative effects of glucose homeostasis with regard to the positive effects seen, further investigations are needed to evaluate the final effect of selenium supplementation in patients with type 2 diabetes. |
- Global report on diabetes: World Health Organization; 2016 [Available from: http://www.who.int/diabetes/global-report/en/.
- IDF Atlas: International Diabetes Federation; 2015 [Seventh:[Available from: http://www.diabetesatlas.org/.
- Federation ID. IRAN: International Diabetes Federation; 2016 [Available from: https://www.idf.org/our-network/regions-members/middle-east-and-north-africa/members/35-iran.html.
- Stapleton SR. Selenium: an insulin-mimetic. Cellular and Molecular Life Sciences. 2000;57(13-14):1874-9.
- Faghihi T, Radfar M, Barmal M, Amini P, Qorbani M, Abdollahi M, et al. A randomized, placebo-controlled trial of selenium supplementation in patients with type 2 diabetes: effects on glucose homeostasis, oxidative stress, and lipid profile. American Journal of Therapeutics. 2014;21(6):491-5.
- Faure P, Ramon O, Favier A, Halimi S. Selenium supplementation decreases nuclear factor‐kappa B activity in peripheral blood mononuclear cells from type 2 diabetic patients. European Journal of Clinical Investigation. 2004;34(7):475-81.
- Farrokhian A, Bahmani F, Taghizadeh M, Mirhashemi S, Aarabi M, Raygan F, et al. Selenium supplementation affects insulin resistance and serum hs-CRP in patients with type 2 diabetes and coronary heart disease. Hormone and Metabolic Research. 2016;48(04):263-8.
- Jamilian M, Razavi M, Fakhrie Kashan Z, Ghandi Y, Bagherian T, Asemi Z. Metabolic response to selenium supplementation in women with polycystic ovary syndrome: a randomized, double‐blind, placebo‐controlled trial. Clinical Endocrinology. 2015;82(6):885-91.
- Yang S, Hwang S, Choi H, Yoo H, Seo J, Kim S, et al. Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: Implications for insulin resistance, inflammation, and atherosclerosis. The Journal of Clinical Endocrinology & Metabolism. 2011;96(8):E1325-E9.
- Kim JE, Choi SI, Lee HR, Hwang IS, Lee YJ, An BS, et al. Selenium significantly inhibits adipocyte hypertrophy and abdominal fat accumulation in OLETF rats via induction of fatty acid beta-oxidation. Biological Trace Element Research. 2012;150(1-3):360-70.
- He Y-T, Liu D-W, Ding L-Y, Li Q, Xiao Y-H. Therapeutic effects and molecular mechanisms of anti-fibrosis herbs and selenium on rats with hepatic fibrosis. World Journal of Gastroenterology. 2004;10(5):703.
- Duntas L. Selenium and inflammation: underlying anti-inflammatory mechanisms. Hormone and Metabolic Research. 2009;41(06):443-7.
- Ozturk IC, Batcioglu K, Karatas F, Hazneci E, Genc M. Comparison of plasma malondialdehyde, glutathione, glutathione peroxidase, hydroxyproline and selenium levels in patients with vitiligo and healthy controls. Indian Journal of Dermatology. 2008;53(3):106.
- Rohr‐Udilova N, Sieghart W, Eferl R, Stoiber D, Björkhem‐Bergman L, Eriksson LC, et al. Antagonistic effects of selenium and lipid peroxides on growth control in early hepatocellular carcinoma. Hepatology. 2012;55(4):1112-21.
- Zeng J, Zhou J, Huang K. Effect of selenium on pancreatic proinflammatory cytokines in streptozotocin-induced diabetic mice. The Journal of Nutritional Biochemistry. 2009;20(7):530-6.
|